Loading...
XNYSCOO
Market cap18bUSD
Dec 27, Last price  
92.34USD
1D
-0.29%
1Q
-15.89%
Jan 2017
111.15%
Name

Cooper Companies Inc

Chart & Performance

D1W1MN
XNYS:COO chart
P/E
46.98
P/S
4.73
EPS
1.97
Div Yield, %
0.00%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
7.98%
Revenues
3.90b
+8.41%
806,617,000858,960,000950,641,0001,063,176,0001,080,421,0001,158,517,0001,330,835,0001,445,136,0001,587,725,0001,717,776,0001,797,060,0001,966,814,0002,139,000,0002,532,800,0002,653,400,0002,430,900,0002,922,500,0003,308,400,0003,593,200,0003,895,400,000
Net income
392m
+33.34%
91,722,00066,234,000-11,192,00065,476,000100,548,000112,803,000175,430,000248,339,000296,151,000269,856,000203,523,000273,917,000372,900,000139,900,000466,700,000238,400,0002,944,700,000385,800,000294,200,000392,300,000
CFO
709m
+16.76%
183,843,000162,716,000133,984,00096,528,000223,128,000267,663,000336,281,000315,121,000415,925,000454,823,000390,970,000509,637,000593,600,000668,900,000713,200,000486,600,000738,600,000692,400,000607,500,000709,300,000
Dividend
Jul 26, 20230.03 USD/sh
Earnings
Feb 26, 2025

Profile

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
URL
https://www.coopercos.com/
IPO date
Jan 21, 1983
Employees
15,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑102015‑10
Income
Revenues
3,895,400
8.41%
3,593,200
8.61%
3,308,400
13.20%
Cost of revenue
1,454,800
1,372,700
1,279,100
Unusual Expense (Income)
NOPBT
2,440,600
2,220,500
2,029,300
NOPBT Margin
62.65%
61.80%
61.34%
Operating Taxes
190,000
118,700
89,500
Tax Rate
7.78%
5.35%
4.41%
NOPAT
2,250,600
2,101,800
1,939,800
Net income
392,300
33.34%
294,200
-23.74%
385,800
-86.90%
Dividends
(3,000)
(3,000)
Dividend yield
0.02%
0.02%
Proceeds from repurchase of equity
8,300
(62,400)
BB yield
-0.04%
0.46%
Debt
Debt current
34,400
45,400
412,600
Long-term debt
5,900
2,528,200
2,371,400
Deferred revenue
184,200
198,300
Other long-term liabilities
3,110,400
329,400
338,400
Net debt
(67,300)
2,452,700
2,521,300
Cash flow
Cash from operating activities
709,300
607,500
692,400
CAPEX
(421,200)
(392,500)
(242,000)
Cash from investing activities
(764,600)
(449,000)
(1,831,200)
Cash from financing activities
39,200
(173,900)
1,193,700
FCF
2,065,100
1,528,000
2,214,700
Balance
Cash
107,600
120,900
138,200
Long term investments
124,500
Excess cash
97,280
Stockholders' equity
6,868,600
6,428,100
6,123,700
Invested Capital
11,231,900
10,633,800
10,377,520
ROIC
20.59%
20.01%
20.09%
ROCE
21.55%
20.68%
19.10%
EV
Common stock shares outstanding
200,400
199,200
198,800
Price
104.68
34.31%
77.94
14.03%
68.35
-34.43%
Market cap
20,977,872
35.12%
15,525,150
14.26%
13,587,483
-34.56%
EV
20,910,772
17,978,250
16,108,983
EBITDA
2,815,700
2,588,200
2,375,400
EV/EBITDA
7.43
6.95
6.78
Interest
114,300
105,300
57,300
Interest/NOPBT
4.68%
4.74%
2.82%